Connecticut Startup Loxo Oncology Reels In $24 Million Series B

Loxo Oncology Closes a $24 Million Series B Financing and Expands Management Team STAMFORD, Conn.-- --Loxo Oncology, Inc., a biopharmaceutical company focused on developing targeted cancer therapies for genetically-defined populations, announced today that it has closed a $24 million Series B private financing round led by New Enterprise Associates ... (more)

http://ift.tt/1fPX1p3